Merck, Eisai discontinuing Phase 3 melanoma combination study

Merck (MRK) and Eisai (ESALY) provided updates on two Phase 3 trials, LEAP-003 and LEAP-017 investigating Keytruda plus Lenvima. Merck and Eisai are discontinuing the Phase 3 LEAP-003 trial evaluating Keytruda plus Lenvima for the first-line treatment of adults with unresectable or metastatic melanoma. The decision is based on the recommendation of an independent Data Monitoring Committee, which reviewed data from a planned interim analysis and determined Keytruda plus Lenvima did not demonstrate an improvement in overall survival, one of the study’s dual primary endpoints, versus Keytruda alone.